Show simple item record

125I seed brachytherapy for non-central pelvic recurrence of cervical cancer after external beam radiotherapy

dc.contributor.authorXuemin Di
dc.contributor.authorZhen Gao
dc.contributor.authorHuimin Yu
dc.contributor.authorXiaoli Liu
dc.contributor.authorJinxin Zhao
dc.contributor.authorJuan Wang
dc.contributor.authorHongtao Zhang
dc.contributor.otherDepartment of Oncology, Hebei General Hospital
dc.contributor.otherDepartment of Oncology, Hebei General Hospital
dc.contributor.otherDepartment of Oncology, Hebei General Hospital
dc.contributor.otherDepartment of Oncology, Hebei General Hospital
dc.contributor.otherDepartment of Oncology, Hebei General Hospital
dc.contributor.otherDepartment of Oncology, Hebei General Hospital
dc.contributor.otherDepartment of Oncology, Hebei General Hospital
dc.date.accessioned2024-06-09T11:28:23Z
dc.date.accessioned2025-10-08T08:22:51Z
dc.date.available2025-10-08T08:22:51Z
dc.date.issued01-06-2024
dc.identifier.urihttp://digilib.fisipol.ugm.ac.id/repo/handle/15717717/35672
dc.description.abstractAbstract Objective To investigate the efficacy of 125I seed brachytherapy for non-central pelvic recurrence of cervical cancer after external beam radiotherapy, and to analyze the clinical influential factors. Methods Between June 2015 and April 2022, 32 patients with 41 lesions were treated with 125I seed brachytherapy. The seeds were implanted under the guidance of CT and/or 3D-printed template images at a median dose of 100 Gy (range, 80–120 Gy), and the local control rate (LCR) and survival rates were calculated. We used multivariate logistic regression to identify prognosis predictors, and receiver operating characteristic (ROC) curve analysis to determine the optimal cut-off values. Results The median follow-up was 48.52 months (range, 4–86 months), and the 6-, 12-, and 24-month LCR was 88.0%, 63.2%, and 42.1%, respectively. The 1- and 2-year survival rates were 36% and 33%, respectively, and the median survival time was 13.26 months. No significant adverse events occurred. Multivariate regression analysis showed that tumor diameter, tumor stage, and LCR were independent factors influencing survival. ROC curve analysis showed that the area under the curve for tumor diameter and D90 were 0.765 and 0.542, respectively, with cut-off values of 5.3 cm and 108.5 Gy. Conclusions The present findings indicate that 125I seed brachytherapy is feasible for treating non-central pelvic recurrence of cervical cancer after external beam radiotherapy. Further, tumor diameter < 5.3 cm and immediate postoperative D90 > 108.5 Gy were associated with better efficacy.
dc.language.isoEN
dc.publisherBMC
dc.subject.lccMedical physics. Medical radiology. Nuclear medicine
dc.title125I seed brachytherapy for non-central pelvic recurrence of cervical cancer after external beam radiotherapy
dc.typeArticle
dc.description.keywordsBrachytherapy
dc.description.keywordsNon-central pelvic recurrence of Cervical Cancer
dc.description.keywordsExternal Beam Radiotherapy
dc.description.keywordsLocoregional
dc.description.keywordsPelvic recurrence
dc.description.pages1-8
dc.description.doi10.1186/s13014-024-02454-1
dc.title.journalRadiation Oncology
dc.identifier.e-issn1748-717X
dc.identifier.oai18d4013415284310be4e24b383c67825
dc.journal.infoVolume 19, Issue 1


This item appears in the following Collection(s)

Show simple item record